About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Col1a1+
wild type
MGI:2440656
Summary 103 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Col1a1Aga2/Col1a1+ C3HeB/FeJ-Col1a1Aga2 MGI:5431996
ht2
Col1a1em1Nju/Col1a1+ C57BL/6-Col1a1em1Nju MGI:7863810
ht3
Col1a1Mov13/Col1a1+ C57BL/6-Col1a1Mov13 MGI:3620077
ht4
Col1a1tm1Jae/Col1a1+ either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6) MGI:2675291
ht5
Col1a1tm1.1Jcm/Col1a1+ either: (involves: 129X1/SvJ * C3H/HeJ) or (involves: 129X1/SvJ * CD-1) MGI:3623489
ht6
Col1a1tm1Jcm/Col1a1+ either: (involves: 129X1/SvJ * C3H/HeJ) or (involves: 129X1/SvJ * CD-1) MGI:3623481
ht7
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5755877
ht8
Col1a1tm1(tetO-Vegfc)Mmul/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5704369
ht9
Col1a1tm1(hs1473-PITX1)Smun/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5529078
ht10
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5755866
ht11
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5569527
ht12
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5755880
ht13
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:5755881
ht14
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:6377632
ht15
Col1a1tm13(tetO-Nup88)Jvd/Col1a1+ involves: 129S4/SvJae * C57BL/6 MGI:6377633
ht16
Col1a1tm1(tetO-Lin28a)Gqda/Col1a1+ involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:4849446
ht17
Col1a1tm1.1Jcm/Col1a1+ involves: 129X1/SvJ MGI:3623487
ht18
Col1a1Aga2/Col1a1+ involves: C3HeB/FeJ * C57BL/6J MGI:3769907
ht19
Col1a1M1Jrt/Col1a1+ involves: C3H/HeJ * C57BL/6J MGI:5689501
ht20
Col1a1M1Jrt/Col1a1+ involves: C3H/HeJ * C57BL/6J * FVB/NJ MGI:5689511
ht21
Col1a1Mov13/Col1a1+ involves: C57BL/6 MGI:3620112
ht22
Col1a1M1Jrt/Col1a1+ involves: C57BL/6 * FVB/N MGI:5791061
cn23
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+ involves: 129S4/SvJae * BALB/c * C57BL/6 MGI:6256822
cn24
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+ involves: 129S4/SvJae * BALB/c * C57BL/6 MGI:5661329
cn25
Col1a1tm5(tetO-Jun/Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N MGI:5586561
cn26
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N MGI:5586562
cn27
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6 MGI:5661330
cn28
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6 MGI:5661331
cn29
Col1a1tm1(CAG-Ezh2*)Meln/Col1a1+
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5519929
cn30
Col1a1tm1(tetO-SOX2)Mjm/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J MGI:5508638
cn31
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J MGI:5508640
cn32
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5638869
cn33
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5638793
cn34
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Myf5tm1(cre)Mrc/Myf5+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5519077
cn35
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA MGI:5316468
cn36
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1 MGI:5638867
cn37
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2 MGI:5705651
cn38
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * ICR MGI:5638874
cn39
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 MGI:4999988
cn40
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 MGI:5485201
cn41
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N MGI:5582197
cn42
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5755868
cn43
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5755878
cn44
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5755879
cn45
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5755882
cn46
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL MGI:4430578
cn47
Col1a1tm8(CAG-BDNF)Jae/Col1a1+
Mecp2tm1.1Jae/Y
Tg(Camk2a-cre)93Kln/0
involves: 129S4/SvJae * C57BL/6 * CBA/J MGI:5306257
cn48
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2 MGI:5485200
cn49
Col1a1tm1(CAG-Sirt2)Jmi/Col1a1+
Tg(Mpz-cre)26Mes/0
involves: 129S4/SvJae * C57BL/6 * FVB/N MGI:5295750
cn50
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Ssttm2.1(cre)Zjh/Sst+
involves: 129S4/SvJae * C57BL/6J MGI:6693445
cn51
Col1a1tm2(CAG-IDH2*R172K)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6 MGI:5582235
cn52
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6 MGI:5582193
cn53
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Tg(Prkcd-glc-1/CFP,-cre)EH124Gsat/0
involves: C57BL/6J * FVB/NTac MGI:6693444
cx54
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd MGI:6378441
cx55
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd MGI:6378452
cx56
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
chimera involves: 129S4/SvJae * C57BL/6 MGI:5000008
cx57
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129 * C57BL/6 MGI:5527337
cx58
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Rag1tm1Mom/Rag1tm1Mom
Tg(KRT5-rtTA)T2D6Sgkd/0
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N MGI:5555860
cx59
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
involves: 129S4/SvJae * C57BL/6 MGI:5316652
cx60
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:3703249
cx61
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4822382
cx62
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999980
cx63
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999985
cx64
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:4999987
cx65
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000007
cx66
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5000010
cx67
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000011
cx68
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5000012
cx69
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5000013
cx70
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5051636
cx71
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304757
cx72
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6 MGI:5304759
cx73
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5316663
cx74
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5430595
cx75
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5485198
cx76
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5585616
cx77
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5586502
cx78
Col1a1tm1(tetO-U2AF1*S34F)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 MGI:5754807
cx79
Col1a1tm2(tetO-U2AF1)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
involves: 129S4/SvJae * C57BL/6 MGI:5754809
cx80
Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5911575
cx81
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5911576
cx82
Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 MGI:5911578
cx83
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313420
cx84
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5469373
cx85
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5437856
cx86
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313423
cx87
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:4430577
cx88
ApcMin/Apc+
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:6377634
cx89
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313421
cx90
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J MGI:5313419
cx91
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5294614
cx92
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5294615
cx93
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S4/SvJae * C57BL/6 * CD-1 MGI:5586499
cx94
Col1a1tm1(tetO-CDKN2A)Ibp/Col1a1+
Tg(KRT5-rtTA)#Glk/0
involves: 129S4/SvJae * C57BL/6 * FVB MGI:5502570
cx95
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
involves: 129S4/SvJae * C57BL/6 * FVB/N MGI:5555858
cx96
Col1a1tm4(tetO-Jun/Fosl2)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5586552
cx97
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5586504
cx98
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5586503
cx99
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000006
cx100
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000009
cx101
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000005
cx102
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI MGI:5000014
cx103
Atg5tm1.1Myok/Atg5tm1.1Myok
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N MGI:5572909


Genotype
MGI:5431996
ht1
Allelic
Composition
Col1a1Aga2/Col1a1+
Genetic
Background
C3HeB/FeJ-Col1a1Aga2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1Aga2 mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice with a severe phenotype display postnatal lethality
• lethality is not rescued by bisphosphonate alendronate treatment
• mice with a mild phenotype survive to adulthood

cardiovascular system
• in mice with a severe phenotype cardiac vessels have disordered cell arrangements and thinner walls
• mice with a severe phenotype display reduction in the amount of collagen and a disordered collagen matrix with fewer and thinner collagen fibrils
• in mice with a severe phenotype
• enlarged septa in mice with a severe phenotype
• mice with a severe phenotype display a septal deformation with a convex bulge into the left ventricle during contraction
• in mice with a severe phenotype
• left ventricular end-systolic internal diameter is increased resulting in a reduced ejection fraction in mice with a severe phenotype
• extended J-T interval in mice with a mild phenotype
• in mice with a mild phenotype

respiratory system
• in mice with a severe phenotype
• infiltrates of polymorphonuclear neutrophils and alveolar macrophages in mice with a severe phenotype

cellular
• cardiac fibroblasts from mice with a severe phenotype show disordered cytoplasm and Golgi abnormalities
• cardiac fibroblasts from mice with a severe or mild phenotype show a strong or slight decrease in collagen staining, respectively
• marginal decrease in collagen in lung fibroblasts from mice with a severe phenotype
• in cardiac fibroblasts
• in cardiac fibroblasts from mice with a severe phenotype

growth/size/body
• in mice with a severe phenotype
• at 6-11 days of age in mice with a mild phenotype weight is 75% that of wild-type mice
• at 6-11 days of age in mice with a severe phenotype weight is 53% that of wild-type mice

skeleton
• rib fractures with callus formation are equally frequent in mice with severe or mild phenotypes

homeostasis/metabolism
• reduction of 44% in arterial pO2 and an increase of 40% in pCO2 accompanied by a 61% decrease in oxygen saturation in mice with a severe phenotype

immune system
• infiltrates of polymorphonuclear neutrophils and alveolar macrophages in mice with a severe phenotype

muscle
• mice with a severe phenotype display reduction in the amount of collagen and a disordered collagen matrix with fewer and thinner collagen fibrils
• in mice with a severe phenotype
• left ventricular end-systolic internal diameter is increased resulting in a reduced ejection fraction in mice with a severe phenotype

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 3 DOID:0110339 OMIM:259420
J:185988




Genotype
MGI:7863810
ht2
Allelic
Composition
Col1a1em1Nju/Col1a1+
Genetic
Background
C57BL/6-Col1a1em1Nju
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1em1Nju mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• body weight is significantly reduced from around 5 weeks of age
• mice exhibit reduced weight gain from around 5 weeks of age

skeleton
• bone surface area/bone volume ratio in femurs is increased (nearly doubled) at 8 weeks but not 20 weeks of age
• adipose-derived mesenchymal stem cells treated with osteogenic induction medium show reduced osteoblast differentiation
• bone mineral content is reduced at 8 and 20 weeks of age
• bone mineral density is reduced at 8 and 20 weeks of age, however mineralization does improve with aging
• however, no differences in cortical bone values are seen
• trabecular bone volume/total volume ratio in femurs is reduced by about half at 8 and 20 weeks of age
• a small reduction in trabecular number in femurs at 20 weeks of age, but not at 8 weeks
• trabecular spacing of femurs is increased at 8 and 20 weeks of age
• trabecular thickness of femurs is reduced at 8 weeks of age and to a lesser degree at 20 weeks of age
• lower serum PINP levels indicating reduction in bone osteogenesis
• lower serum PINP and higher CTX-I levels indicating weakened collagen secretion and unusually active degradation; PINP production reduces but CTX-I level remains stable with age, indicating a sustained bone absorption
• both the percentage and number of TRAP+ osteoclasts on the trabecular surface is increased indicating continuously active osteoclasts
• femurs exhibit decreased stiffness at 8 and 20 weeks of age
• while stiffness increases by 20 weeks of age, stiffness is still smaller than in wild-type at this age
• lower mechanical strength
• femurs bare a smaller maximum load
• while maximum load increases by 20 weeks of age, they are still smaller than in wild-type at this age
• femurs exhibit reduced post-yield displacement and plasticity
• femurs exhibit lower post-yield displacement, post-yield energy, and work-to-fracture indicating more brittle bones
• however, no spontaneous fractures are seen

cellular
• adipose-derived mesenchymal stem cells treated with osteogenic induction medium show reduced osteoblast differentiation

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 1 DOID:0110334 OMIM:166200
J:358220




Genotype
MGI:3620077
ht3
Allelic
Composition
Col1a1Mov13/Col1a1+
Genetic
Background
C57BL/6-Col1a1Mov13
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1Mov13 mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
pigmentation
• between 6-8 weeks of age, many single, interspersed hairs turn white, indicating premature hair color change

integument
• between 6-8 weeks of age, many single, interspersed hairs turn white, indicating premature hair color change




Genotype
MGI:2675291
ht4
Allelic
Composition
Col1a1tm1Jae/Col1a1+
Genetic
Background
either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1Jae mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• collagen accumulation in the uteri of heterozygous mutants was less pronounced relative to homozygous mutants
• heterozygous females had slightly reduced litter sizes and significantly fewer litters than wild-type females

integument
• heterozygotes developed patchy hair loss
• at ~7 months, heterozygotes developed dermal fibrosis, similar to scleroderma, and skin ulcerations
• mutant skin displayed a significant increase in collagen extending through to the deep dermis
• heterozygous males and females developed similar but milder skin abnormalities relative to age-matched homozygous males




Genotype
MGI:3623489
ht5
Allelic
Composition
Col1a1tm1.1Jcm/Col1a1+
Genetic
Background
either: (involves: 129X1/SvJ * C3H/HeJ) or (involves: 129X1/SvJ * CD-1)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1.1Jcm mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Skeletal abnormalities and small size of Col1a1tm1.1Jcm/Col1a1+ mice

mortality/aging
• 40-60% of F2 pups die within a few hours after birth from respiratory distress

growth/size/body
• pulp cavity of molars appears necrotic and infected with bacteria
• nasal turbinates show a presence of osteoid proliferation and tissue composed of fibroblasts rather than mature bone
• thorax has a narrow apex and flared base
• size is about 50% that of wild-type until 6 weeks of age, after which size increases to about 80% of normal

respiratory system
• pulmonary hemorrhage is seen in embryos
• nasal turbinates show a presence of osteoid proliferation and tissue composed of fibroblasts rather than mature bone
• 40-60% of F2 pups die within a few hours after birth from respiratory distress

skeleton
• calvarium is thinner and poorly mineralized
• pulp cavity of molars appears necrotic and infected with bacteria
• show disorganized islands of bone formation in the maxilla in the area around the molars
• nasal turbinates show a presence of osteoid proliferation and tissue composed of fibroblasts rather than mature bone
• exhibit long bone fractures
• ramus of ischium appears to be laterally flared
• multiple rib fractures
• gracile ribs
• deformed and flared rib cage
• vertebral bodies are disorganized, osteoporotic, shorter, and flattened
• general undermineralization of the skeleton, especially of the skull

limbs/digits/tail
• fore and hind legs are bowed and thinner than wild-type

cardiovascular system
• pulmonary hemorrhage is seen in embryos

craniofacial
• calvarium is thinner and poorly mineralized
• pulp cavity of molars appears necrotic and infected with bacteria
• show disorganized islands of bone formation in the maxilla in the area around the molars
• nasal turbinates show a presence of osteoid proliferation and tissue composed of fibroblasts rather than mature bone

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 4 DOID:0110340 OMIM:166220
J:59168




Genotype
MGI:3623481
ht6
Allelic
Composition
Col1a1tm1Jcm/Col1a1+
Genetic
Background
either: (involves: 129X1/SvJ * C3H/HeJ) or (involves: 129X1/SvJ * CD-1)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1Jcm mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Skeletal abnormalities in Col1a1tm1.1Jcm/Col1a1+ and Col1a1tm1Jcm/Col1a1+ mice

mortality/aging
• F1 heterozygotes die a few hours after birth from respiratory distress

respiratory system
• F1 heterozygotes die a few hours after birth from respiratory distress

skeleton
• decrease in calvarial mineralization
• exhibit multiple rib fractures
• short vertebral bodies

craniofacial
• decrease in calvarial mineralization

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 2 DOID:0110341 OMIM:166210
J:59168




Genotype
MGI:5755877
ht7
Allelic
Composition
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm18(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal crypt proliferation, differentiation and Paneth cell production




Genotype
MGI:5704369
ht8
Allelic
Composition
Col1a1tm1(tetO-Vegfc)Mmul/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Vegfc)Mmul mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• mice homozygous for this allele exhibit no apparent abnormality.




Genotype
MGI:5529078
ht9
Allelic
Composition
Col1a1tm1(hs1473-PITX1)Smun/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(hs1473-PITX1)Smun mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
limbs/digits/tail
• resembling the shape of the calcaneus of the hindlimb
• digit I has two phalanges
• two digits are missing
• digit I and II are fused
• forelimb-to-hindlimb transformation
• the distal head of the humerus is more similar to the distal femur
• loss of the olecranon
• only one zeugopod bone present resembling the shape of the tibia at the proximal head

skeleton
• resembling the shape of the calcaneus of the hindlimb
• the distal head of the humerus is more similar to the distal femur




Genotype
MGI:5755866
ht10
Allelic
Composition
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm17(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal crypt proliferation, differentiation and Paneth cell production




Genotype
MGI:5569527
ht11
Allelic
Composition
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• reduced multipotent neurospheres, neurosphere size and self-renewal potential in doxycycline-treated mice




Genotype
MGI:5755880
ht12
Allelic
Composition
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm19(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal crypt proliferation, differentiation and Paneth cell production




Genotype
MGI:5755881
ht13
Allelic
Composition
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal crypt proliferation, differentiation and Paneth cell production




Genotype
MGI:6377632
ht14
Allelic
Composition
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO-Nup88)Jvd mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• dox-treated MEFs exhibit higher aneuploidy rates
• splenocytes from 5 month old dox-treated mice show about 4-fold higher rates of aneuploidy than control splenocytes
• lung tissues from 5 month old dox-treated mice are more aneuploid than control lung tissues
• dox-treated MEFs exhibit mitotic checkpoint defects
• dox-treated MEFs have higher rates of chromatin bridges and lagging chromosomes, indicating chromosomal segregation defects
• dox-treated MEFs exhibit increased incomplete centrosome separation
• MEFs treated with the PLK inhibitor BI2536 show restoration of normal centrosome separation
• dox-treated MEFs exhibit more frequent spindle geometry defects showing mitotic spindle asymmetry

neoplasm
• mice administered doxycycline (dox) beginning at weaning are prone to spontaneous tumors, particularly lung tumors, by 14 months of age, with 56% of mice having at least one neoplastic lesion compared to 21% of controls
• in dox-treated mice

respiratory system
• in dox-treated mice




Genotype
MGI:6377633
ht15
Allelic
Composition
Col1a1tm13(tetO-Nup88)Jvd/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm13(tetO-Nup88)Jvd mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• dox-treated MEFs exhibit higher aneuploidy rates
• splenocytes from 5 month old dox-treated mice show about 4-fold higher rates of aneuploidy than control splenocytes
• lung tissues from 5 month old dox-treated mice are more aneuploid than control lung tissues
• dox-treated MEFs exhibit mitotic checkpoint defects
• dox-treated MEFs have higher rates of chromatin bridges and lagging chromosomes, indicating chromosomal segregation defects
• dox-treated MEFs exhibit increased incomplete centrosome separation
• MEFs treated with the PLK inhibitor BI2536 show restoration of normal centrosome separation
• dox-treated MEFs exhibit more frequent spindle geometry defects showing mitotic spindle asymmetry

neoplasm
• mice administered doxycycline (dox) beginning at weaning are prone to spontaneous tumors, particularly lung tumors, by 14 months of age, with 56% of mice having at least one neoplastic lesion compared to 21% of controls
• in dox-treated mice

respiratory system
• in dox-treated mice




Genotype
MGI:4849446
ht16
Allelic
Composition
Col1a1tm1(tetO-Lin28a)Gqda/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Lin28a)Gqda mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following induction with doxycycline associated with marked gut pathology

reproductive system
N
• despite delayed sexual maturation in female mice, fertility over the first 3 months of life is normal
• time to first litter is delayed compared with wild-type mice
• however, timing of first estrus is normal
• puberty is delayed in female mice compared with wild-type mice
• at P26, uterine plus ovarian mass is less than in wild-type mice indicating delayed sexual development
• however, timing of first estrus is normal
• in the first litter

growth/size/body
• mice exhibit wider faces compared with wild-type mice
• increase in the percentage of lean mass
• gain less fat mass with age compared to wild-type mice on a normal diet
• gain less fat mass when fed a high fat diet compared to wild-type mice
• no difference in the consumption of high fat food is detected
• regardless of doxycycline induction
• after weaning
• after weaning
• mice exhibit an increase in cell number compared with wild-type mice without a change in cell size

homeostasis/metabolism
• gain less fat mass when fed a high fat diet compared to wild-type mice
• no difference in the consumption of high fat food is detected
• in fed and fasted states
• after glucose stimulation
• without increased insulin secretion (J:166568)
• under high fat diet conditions (J:177113)
• under high fat diet conditions (J:177113)

skeleton
• mice exhibit large bones compared with wild-type mice
• mice exhibit bone hyperplasia compared with wild-type mice
• bone mineral content is increased compared to in wild-type mice
• bone mineral density is increased compared to in wild-type mice

craniofacial
• mice exhibit wider faces compared with wild-type mice

liver/biliary system
• mice exhibit an increase in cell number compared with wild-type mice without a change in cell size
• mice exhibit an increase in cell number compared with wild-type mice without a change in cell size

cellular
• doxycycline-treated mice exhibit an increase in cell proliferation in the intestinal crypts, blood, and skin compared with wild-type mice
• mice exhibit cell hyperplasia without an increase in cell size
• mice exhibit an increase in cell number compared with wild-type mice without a change in cell size

digestive/alimentary system
• following induction with doxycycline, mice exhibit marked gut pathology unlike wild-type mice

hearing/vestibular/ear

endocrine/exocrine glands

integument

adipose tissue
• decrease in the percentage of body fat




Genotype
MGI:3623487
ht17
Allelic
Composition
Col1a1tm1.1Jcm/Col1a1+
Genetic
Background
involves: 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1.1Jcm mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• some F1 pups die within 3-4 hours after birth from respiratory distress, although some survive past 1 year of age

growth/size/body
• those surviving the neonatal period are 50-80% the size of wild-type

respiratory system
• some F1 pups die within 3-4 hours after birth from respiratory distress

skeleton
• F1 pups exhibit a decrease in calvarial mineralization
• F1 pups exhibit multiple rib fractures
• F1 pups have shorter vertebral bodies
• F1 pups exhibit a decrease in calvarial mineralization

craniofacial
• F1 pups exhibit a decrease in calvarial mineralization




Genotype
MGI:3769907
ht18
Allelic
Composition
Col1a1Aga2/Col1a1+
Genetic
Background
involves: C3HeB/FeJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1Aga2 mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Col1a1Aga2/Col1a+ mice display skeletal and growth abnormalities

mortality/aging
• large subset of heterozygotes die postnatally

cellular
• formation of bone-like nodules by cultured calvarial osteoblasts (OBs) is reduced between 9 and 16 days in culture compared to wild-type cells; average area of individual nodules is reduced relative to controls
• nodular Alizarin red-binding capacity (staining for calcium in bone) is reduced 3.2 fold, indicative of decreased calcium deposition by osteoblasts
• after induction of cytoprotective unfolded protein response in cultured calvarial OBs, apoptosis is elevated compared to controls, with a 10% relative increase in TUNEL-positive picnotic OBs at 16 days in culture

growth/size/body
• animals are smaller than wild-type littermates; at 9 weeks, all animals examined have 'slender' bodies relative to controls
• at 16 weeks, average body mass is ~20 grams compared to wild-type body mass of ~32 grams
• at 16 weeks, average body length is ~8.9 cm compared to ~10 cm in wild-type

nervous system
• intracranial hemorrhages are seen in subset of heterozygotes that die postnatally

skeleton
• formation of bone-like nodules by cultured calvarial osteoblasts (OBs) is reduced between 9 and 16 days in culture compared to wild-type cells; average area of individual nodules is reduced relative to controls
• nodular Alizarin red-binding capacity (staining for calcium in bone) is reduced 3.2 fold, indicative of decreased calcium deposition by osteoblasts
• after induction of cytoprotective unfolded protein response in cultured calvarial OBs, apoptosis is elevated compared to controls, with a 10% relative increase in TUNEL-positive picnotic OBs at 16 days in culture
• skeletal phenotype is detectable between 6 and 11 days after birth
• animals reaching adulthood display mildly to moderately dystrophic limbs
• subset of heterozygotes that die postnatally show thin calvaria
• femoral periosteum at 12 weeks displays greater caspase 3-immunoreactivity indicating an elevated basal level of apoptosis (~14% higher relative to controls); an increased number of TUNEL-positive cells is observed in periosteum also
• at 21 weeks, mediolateral shaft diameter is ~1.45 mm, compared to ~1.88 in wild-type
• at 21 weeks, femur length of heterzygotes is ~14.7 mm, compared to ~15.3 mm in wild-type
• ~50% of animals have deformed fibulae at 16 weeks of age
• at 16 weeks, all animals examined show pelvic girdle bone abnormalities including deteriorated ischium
• at 16 weeks, all animals examined show pelvic girdle bone abnormalities including deteriorated pubis region
• at 16 weeks, all animals examined show kyphoscoliosis
• at 16 weeks, bone mineral content is ~309 mg compared to ~935 mg in wild-type animals
• at 16 weeks, bone mineral density (without head) is 42 mg/cm2 compared to ~58 mg/cm2 in wild-type
• cortical structure has less-parallel, less-densely packed network of collagen bundles compared to controls
• cultured primary calvarial osteoblasts (OBs) show growth anomalies, with stimulated OBs displaying a limited saturation density
• at 16 weeks, significant numbers of heterozygotes show a variety of bone fractures, including the tibia, humerus, ulna, and radius whereas no fractures are observed in wild-type

limbs/digits/tail
• femoral periosteum at 12 weeks displays greater caspase 3-immunoreactivity indicating an elevated basal level of apoptosis (~14% higher relative to controls); an increased number of TUNEL-positive cells is observed in periosteum also
• at 21 weeks, mediolateral shaft diameter is ~1.45 mm, compared to ~1.88 in wild-type
• at 21 weeks, femur length of heterzygotes is ~14.7 mm, compared to ~15.3 mm in wild-type
• ~50% of animals have deformed fibulae at 16 weeks of age

craniofacial
• subset of heterozygotes that die postnatally show thin calvaria

homeostasis/metabolism
• total alkaline phosphatase levels are significantly elevated compared to wild-type littermates at 16 weeks
• mice have elevated calcitonin levels (pg/ml), compared to controls; elevation is more pronounced in female heterozygotes
• mice have elevated parathyroid hormone (PTH) levels (pg/ml), compared to wild-type littermates

reproductive system
• female heterozygotes produce smaller litters as result of reduced body size

cardiovascular system
• subset of heterozygotes that die postnatally show hemorrhaging at joint cavities
• intracranial hemorrhages are seen in subset of heterozygotes that die postnatally

adipose tissue
• at 16 weeks, subcutaneous fat span is ~2.9 mm compared to ~5.1 mm in wild-type

integument
• dermis contains more heterogeneous populations of fibroblasts with smaller nuclei, aberrant dilated electron-dense endoplasmic reticula (ERs), lysosomes, and empty autophagic-like vacuoles interspersed throughout the cells

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 2 DOID:0110341 OMIM:166210
J:129569




Genotype
MGI:5689501
ht19
Allelic
Composition
Col1a1M1Jrt/Col1a1+
Genetic
Background
involves: C3H/HeJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1M1Jrt mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• low bone mineral density
• high incidence of bone fractures in affected mice

behavior/neurological
• some affected mice show difficulty walking
• overall physical weakness




Genotype
MGI:5689511
ht20
Allelic
Composition
Col1a1M1Jrt/Col1a1+
Genetic
Background
involves: C3H/HeJ * C57BL/6J * FVB/NJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1M1Jrt mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• myocardial hypertrophy detected upon necropsy at 20-25 weeks of age
• dentin is abnormally mineralized
• no evidence of malocclusion or dentinogenesis imperfecta
• although born phenotypically normal, by 3 weeks of age, both male and female mice are visibly smaller than wild-type controls
• significant reduction in body weight evident at 3 weeks and throughout life
• by 3 weeks of age, both male and female mice are leaner than wild-type controls

behavior/neurological
• flaccid tails by 3 weeks of age
• by 8 weeks of age, some mice begin to show a wobbly and uneven gait that becomes more pronounced with age

skeleton
• dentin is abnormally mineralized
• no evidence of malocclusion or dentinogenesis imperfecta
• degenerative joint disease detected upon necropsy at 20-25 weeks of age
• early onset osteoarthritis
• normal femoral cortical thickness but significantly decreased femoral cross-sectional area and polar moment of inertia
• destructive 3-point bending of femurs revealed significantly weaker, less tough, less stiff, and more brittle bones, with a 39% decrease in strength, a 89% decrease in toughness and a 77% decrease in failure strain but no significant change in the elastic modulus
• tendon collagen fibrils are significantly smaller in diameter
• tendon teased out from the tail is more frayed than normal
• tendon is easily torn during normal dissection
• at 8 weeks of age, 48% of male and 28% of female mice display noticeable curvature of the spine in X-ray images
• bone collagen fibrils are significantly smaller in diameter
• at all ages tested
• at all ages tested
• decreased trabecular bone volume/tissue volume (Tb. BV/TV) in both femoral and vertebral (lumbar vertebrae) bones
• drastic reduction in mechanical and material properties in cortical bone, as assessed by 3-point bending of femurs
• significantly increased osteoblast surface at 8 weeks of age
• osteoblasts show distended endoplasmic reticulum, suggesting that abnormal collagen chains accumulate intracellularly
• significantly increased osteoblast number at 8 weeks of age
• in the femoral metaphysis, low Tb. BV/TV is associated with an increase in trabecular separation and a decrease in trabecular number but not in trabecular thickness
• in lumbar vertebrae, low BV/TV is associated with a decrease in trabecular separation, trabecular number, and trabecular thickness
• higher structure model index (SMI), indicating decreased structural quality, at both bone sites
• in both femoral and vertebral (lumbar vertebrae) bones
• only in lumbar vertebrae
• only in the femoral metaphysis
• only in lumbar vertebrae
• in trabecular bone, calcein labels, where present, are generally diffuse, suggesting impaired and disorganized mineralization
• in vitro, the total number of mesenchymal progenitors (CFU-F) and osteoprogenitors (CFU-ALP) is normal, but the number of mineralized osteoblast colonies (CFU-O) is significantly decreased in stromal cells from 5-wk-old but not 20-wk-old mice relative to wild-type controls
• although osteoclast surface and number are not significantly altered at 8 weeks, serum from both 5-wk and 20-wk-old show higher concentrations of CTX-1, a marker of bone resorption, than that from wild-type controls
• in vitro, osteoclast number and size in spleen-derived cultures are normal
• by 8 weeks of age
• by 8 weeks of age, bones are soft and friable upon cutting
• multiple fractures evident in X-rays, with age- and bone-site related variation in the % of affected mice
• in young mice, most common fracture sites include the pelvis, olecranon process, and zygomatic arch, with frequencies of 82%, 80%, and 68% of mice, respectively
• the % of mice with fractured tarsals increases from 20% at 8 weeks to 58% at 20 weeks of age
• the % of mice with fractured scapulae and arthritic knees increases between 8 and 20 weeks of age (28% to 63% and 0% to 33% for scapulae and knees, respectively)
• significant number of mice with fractured tibial and fibular bones at 30 and 50 weeks of age
• however, no gross skeletal structural anomalies or detectable fractures at E18.5 or at birth

limbs/digits/tail
• normal femoral cortical thickness but significantly decreased femoral cross-sectional area and polar moment of inertia
• destructive 3-point bending of femurs revealed significantly weaker, less tough, less stiff, and more brittle bones, with a 39% decrease in strength, a 89% decrease in toughness and a 77% decrease in failure strain but no significant change in the elastic modulus
• thin tails by 3 weeks of age

muscle
• myocardial hypertrophy detected upon necropsy at 20-25 weeks of age
• tendon collagen fibrils are significantly smaller in diameter
• tendon teased out from the tail is more frayed than normal
• tendon is easily torn during normal dissection

integument
• in vitro, collagen fibrils are significantly smaller in diameter in extracellular matrices deposited by dermal fibroblasts
• skin is more easily torn but of normal thickness
• tensile tests suggested that skin has a lower failure strain, is less extensible with a lower failure displacement, and requires less energy to failure

homeostasis/metabolism
N
• normal plasma biochemical parameters, including concentrations of alkaline phosphatase, calcium, phosphorus, magnesium, cholesterol, triglycerides, glucose, and creatinine, at 16 weeks of age
• total collagen content of extracellular matrices deposited in long-term cultures of dermal fibroblasts is ~40% that of wild-type controls
• type V and III collagens are not altered, but type I collagen in mutant matrices is reduced to only ~30% of that in wild-type cultures, such that the relative amounts of types V and III collagen to the total are increased, whereas that of type I collagen is decreased

craniofacial
• dentin is abnormally mineralized
• no evidence of malocclusion or dentinogenesis imperfecta

cardiovascular system
• myocardial hypertrophy detected upon necropsy at 20-25 weeks of age

immune system
• degenerative joint disease detected upon necropsy at 20-25 weeks of age
• early onset osteoarthritis

adipose tissue
• significant reduction in percent body fat at 3 weeks and throughout life

cellular
• extracellular matrices deposited in long-term cultures of dermal fibroblasts appear more fragile and are easily dislodged from the plate by physical disturbance

reproductive system
• poor breeding success

hearing/vestibular/ear
N
• normal hearing as indicated by clickbox hearing tests




Genotype
MGI:3620112
ht21
Allelic
Composition
Col1a1Mov13/Col1a1+
Genetic
Background
involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1Mov13 mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hearing/vestibular/ear
• profound and progressive hearing loss with age
• profound and progressive hearing loss with age

skeleton
• modulus of elasticity of cortical bone is lower
• disorganized cortical bone, with bone cells not organized in a normal osteonal pattern and diorganization of collagen within the cortex
• exhibit a significant difference in the load deformation response of bones at failure, indicating brittle and fragile bones, however stiffness is normal
• modulus of elasticity of cortical bone is lower

integument
• dermis contains unusually thin collagen fibers and collagen content in the dermis is reduced by about 50%

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 1 DOID:0110334 OMIM:166200
J:107045




Genotype
MGI:5791061
ht22
Allelic
Composition
Col1a1M1Jrt/Col1a1+
Genetic
Background
involves: C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1M1Jrt mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• mice exhibit substantial limping
• mice show decreased rearing attempts
• mice travel less distance in the open field glass chamber compared to wild-type mice
• overall counts of rotations in a home cage running wheel for one hour are reduced
• mice show decreased paw withdrawal thresholds to mechanical stimulation indicating increased sensitivity to mechanical stimuli
• mice show decreased withdrawal latency to heat stimuli indicating increased heat sensitivity
• mice show increased behavioral responses to acetone indicating increased sensitivity to cold stimuli

growth/size/body

homeostasis/metabolism
• improper healing of the femur at the hip joint
• hyperplastic callus formation of olecranon process

immune system
• arthritic knees

limbs/digits/tail
• hindpaw bone deformities
• deformity and fracture of olecranon processes
• hyperplastic callus formation of olecranon process

skeleton
• improper healing of the femur at the hip joint
• hyperplastic callus formation of olecranon process
• arthritic knees
• deformity and fracture of olecranon processes
• hyperplastic callus formation of olecranon process
• reduction in cervical intervertebral disc space
• scoliosis-like spine deformity
• decrease in bone volume/tissue volume
• decrease in cortical thickness
• atlanto-occipital joint dislocation
• deformity and fracture of olecranon processes
• tarsal-metatarsal fracture

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
osteogenesis imperfecta type 4 DOID:0110340 OMIM:166220
J:228439




Genotype
MGI:6256822
cn23
Allelic
Composition
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
Genetic
Background
involves: 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop lung adenocarcinoma 8 weeks after adenoviral cre recombinase instillation and exhibit multi-focal tumors
• treatment together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab induces marked tumor shrinkage

respiratory system
• mice develop lung adenocarcinoma 8 weeks after adenoviral cre recombinase instillation and exhibit multi-focal tumors
• treatment together with the compound EAI045 (an allosteric tyrosine kinase inhibitor) and cetuximab induces marked tumor shrinkage

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
J:235747




Genotype
MGI:5661329
cn24
Allelic
Composition
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Genetic
Background
involves: 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 40% of mice develop lung tumors with an average latency of about 64 weeks after intranasal delivery of an adenovirus expressing cre recombinase

respiratory system
• 40% of mice develop lung tumors with an average latency of about 64 weeks after intranasal delivery of an adenovirus expressing cre recombinase

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
J:214230




Genotype
MGI:5586561
cn25
Allelic
Composition
Col1a1tm5(tetO-Jun/Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-Jun/Fos)Wag mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Alb1-cre)7Gsc mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice develop lethal liver dysplasia

liver/biliary system
• doxycycline-treated mice develop lethal liver dysplasia




Genotype
MGI:5586562
cn26
Allelic
Composition
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Alb1-cre)7Gsc mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice develop lethal liver dysplasia

liver/biliary system
• doxycycline-treated mice develop lethal liver dysplasia




Genotype
MGI:5661330
cn27
Allelic
Composition
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Trp53tm1Brn mutation (21 available); any Trp53 mutation (249 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 92% of mice develop lung tumors with a latency of 28-32 weeks after intranasal delivery of an adenovirus expressing cre recombinase (Ad-cre)
• mice with lung tumors treated with a pan-FGFR inhibitor, BGJ-398, mice show more than 50% tumor regression
• tumors from Ad-cre treated mice resemble poorly differentiated human grade 3/4 lung adenocarcinoma displaying high pleiotropy and heavily multinucleated tumor cells showing local invasion throughout the lung parenchyma

growth/size/body
• Ad-cre treated mice that become sick present with weight loss

mortality/aging
• mice show a decrease in overall survival after Ad-cre treatment, beginning to die around 20 weeks after Ad-cre delivery and most dying by 50 weeks after Ad-cre administration

respiratory system
• 92% of mice develop lung tumors with a latency of 28-32 weeks after intranasal delivery of an adenovirus expressing cre recombinase (Ad-cre)
• mice with lung tumors treated with a pan-FGFR inhibitor, BGJ-398, mice show more than 50% tumor regression
• tumors from Ad-cre treated mice resemble poorly differentiated human grade 3/4 lung adenocarcinoma displaying high pleiotropy and heavily multinucleated tumor cells showing local invasion throughout the lung parenchyma
• Ad-cre treated mice that become sick present with progressive dyspnea and weight loss

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
J:214230




Genotype
MGI:5661331
cn28
Allelic
Composition
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Trp53tm1Brn mutation (21 available); any Trp53 mutation (249 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop lung tumors with a longer latency than seen in Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw mice after intranasal delivery of an adenovirus expressing cre recombinase, with a penetrance of 35%

respiratory system
• mice develop lung tumors with a longer latency than seen in Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw mice after intranasal delivery of an adenovirus expressing cre recombinase, with a penetrance of 35%

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
J:214230




Genotype
MGI:5519929
cn29
Allelic
Composition
Col1a1tm1(CAG-Ezh2*)Meln/Col1a1+
Ighg1tm1(cre)Cgn/Ighg1+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(CAG-Ezh2*)Meln mutation (0 available); any Col1a1 mutation (166 available)
Ighg1tm1(cre)Cgn mutation (4 available); any Ighg1 mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• mice exhibit normal marginal zone and follicular B cells
• following immunization with NP-KLH
• following immunization with NP-KLH
• following immunization with NP-KLH

neoplasm
N
• mice exhibit normal marginal zone and follicular B cells

hematopoietic system
• following immunization with NP-KLH
• following immunization with NP-KLH
• following immunization with NP-KLH




Genotype
MGI:5508638
cn30
Allelic
Composition
Col1a1tm1(tetO-SOX2)Mjm/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-SOX2)Mjm mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(tTA)Roos mutation (3 available); any Gt(ROSA)26Sor mutation (1098 available)
Lgr5tm1(cre/ERT2)Cle mutation (1 available); any Lgr5 mutation (58 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• lyzsozyme+ Paneth cells in doxycycline-treated mice are not restricted to the base of the crypt unlike in control cells
• expanded crypts in the ileum of doxycycline-treated mice
• increased cell proliferation in the intestine of doxycycline-treated mice with an increase in intestinal stem Lgr5+ cells
• increased proliferation of intestinal stem cells in the intestine of doxycycline-treated mice
• expansion of intestinal stem cells is cell autonomous in doxycycline treated mice

cellular
• in the intestine of doxycycline-treated mice with an increase in Lgr5+ intestinal stem cells
• increased proliferation of intestinal stem cells in the intestine of doxycycline-treated mice
• expansion of intestinal stem cells is cell autonomous in doxycycline treated mice

endocrine/exocrine glands
• lyzsozyme+ Paneth cells in doxycycline-treated mice are not restricted to the base of the crypt unlike in control cells
• expanded crypts in the ileum of doxycycline-treated mice




Genotype
MGI:5508640
cn31
Allelic
Composition
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Pou5f1)Jae mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(tTA)Roos mutation (3 available); any Gt(ROSA)26Sor mutation (1098 available)
Lgr5tm1(cre/ERT2)Cle mutation (1 available); any Lgr5 mutation (58 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• expanded crypts in the ileum of doxycycline-treated mice
• increased cell proliferation in the intestine of doxycycline-treated mice without an increase in Lgr5+ cells

cellular
• in the intestine of doxycycline-treated mice without an increase in Lgr5+ cells

endocrine/exocrine glands
• expanded crypts in the ileum of doxycycline-treated mice




Genotype
MGI:5638869
cn32
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Foxd1tm1(GFP/cre)Amc mutation (1 available); any Foxd1 mutation (13 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• mice develop hydronephrosis following doxycycline induction

neoplasm
N
• mice do not develop renal tumors following doxycycline induction




Genotype
MGI:5638793
cn33
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Wt1tm2(cre/ERT2)Wtp mutation (1 available); any Wt1 mutation (34 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• all mice develop kidney tumors within the first 2 weeks of life following doxycycline (Dox) induction during embryonic development at E0, E14.5 or E18.5
• tumors resemble Wilms tumor
• mice treated with doxycycline at P10 do not develop tumors

renal/urinary system
• mice treated with doxycycline at P10 develop cystic kidneys
• all mice develop kidney tumors within the first 2 weeks of life following doxycycline (Dox) induction during embryonic development at E0, E14.5 or E18.5
• tumors resemble Wilms tumor
• mice treated with doxycycline at P10 do not develop tumors
• doxycycline induced mice exhibit persistent proliferation of cap mesenchyme cells in adults
• however, cap mesenchyme cells within tumors retain a differentiation capacity that recapitulates normal kidney development
• timing of kidney development is prolonged in doxycycline induced mice, with sustaining proliferation of the cap mesenchyme cells into adulthood

growth/size/body
• mice treated with doxycycline at P10 develop cystic kidneys

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
nephroblastoma DOID:2154 OMIM:194070
J:211179




Genotype
MGI:5519077
cn34
Allelic
Composition
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Myf5tm1(cre)Mrc/Myf5+
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Myf5tm1(cre)Mrc mutation (1 available); any Myf5 mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• dwarfism in male and female mice




Genotype
MGI:5316468
cn35
Allelic
Composition
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-YAP1*)Fcam mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(KRT14-cre)1Amc mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• skin grafts on nude mice treated with doxycycline exhibit stunted hair growth unlike control grafts
• doxycycline-treated mice exhibit multi-layered epithelium unlike control mice
• skin grafts on nude mice treated with doxycycline exhibit hyperkeratosis unlike control grafts
• skin grafts on nude mice treated with doxycycline exhibit hyperkeratosis unlike control grafts
• 8 days after doxycycline treatment
• 8 days after doxycycline treatment
• skin from doxycycline-treated mice exhibit a greater than 5-fold increase in the number of colony-forming cells compared with skin from control mice
• in nude mice receiving skin grafts and treated with doxycycline

craniofacial
• thickened and dysplastic in doxycycline-treated mice

neoplasm
• in nude mice receiving skin grafts and treated with doxycycline

cellular
• doxycycline-treated mice exhibit increased cell proliferation of basal cells and an extension of the proliferative domain into the suprabasal layers of back skin compared with control mice

digestive/alimentary system
• thickened and dysplastic in doxycycline-treated mice

growth/size/body
• thickened and dysplastic in doxycycline-treated mice




Genotype
MGI:5638867
cn36
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Six2-EGFP/cre)1Amc mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• mice develop cystic kidneys when transgene expression is induced with doxycycline early in embryonic development or in adult mice

neoplasm
N
• mice do not develop renal tumors following doxycycline induction

growth/size/body
• mice develop cystic kidneys when transgene expression is induced with doxycycline early in embryonic development or in adult mice




Genotype
MGI:5705651
cn37
Allelic
Composition
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-YAP1*)Fcam mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Pbsn-cre)4Prb mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age
• tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

endocrine/exocrine glands
• 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age
• tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

reproductive system
• 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age
• tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors




Genotype
MGI:5638874
cn38
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
Genetic
Background
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * ICR
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Cdh16-cre)91Igr mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
N
• no kidney pathology is seen in mice induced with doxycycline




Genotype
MGI:4999988
cn39
Allelic
Composition
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(Luc)Kael mutation (3 available); any Gt(ROSA)26Sor mutation (1098 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
Krastm4Tyj mutation (12 available); any Kras mutation (88 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit reduced survival compared with control mice

neoplasm
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit increased tumor incidence (size and number) in the lungs with rare noninvasive lung adenomas compared with control mice
• however, mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit tumor regression after doxycycline removal
• in mice treated with a cre-expressing adenovirus and treated with doxycycline

respiratory system
• in mice treated with a cre-expressing adenovirus and treated with doxycycline
• rapid shallow breathing in mice treated with a cre-expressing adenovirus and treated with doxycycline

growth/size/body
• in mice treated with a cre-expressing adenovirus and treated with doxycycline




Genotype
MGI:5485201
cn40
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
Genetic
Background
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(EYFP)Cos mutation (23 available); any Gt(ROSA)26Sor mutation (1098 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(Mpz-cre)94Imeg mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• in of all doxycycline-treated mice arising from neural crest-lineage cells




Genotype
MGI:5582197
cn41
Allelic
Composition
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Tmem163Tg(ACTB-cre)2Mrt/0
Genetic
Background
involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(CAG-IDH2*R140Q)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Tmem163Tg(ACTB-cre)2Mrt mutation (3 available); any Tmem163 mutation (37 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice that survive the embryonic period die between 3 and 7 weeks of age

growth/size/body
• surviving mice are runted

cardiovascular system

behavior/neurological

nervous system

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
D-2-hydroxyglutaric aciduria DOID:0050575 OMIM:PS600721
J:209629




Genotype
MGI:5755868
cn42
Allelic
Composition
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm17(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• increased in doxycycline-treated mice
• doxycycline-treated mice exhibit dramatic hyper-proliferation and crypt expansion, blocked differentiation and ectopic Paneth cell production compared with control mice
• increased in doxycycline-treated mice

endocrine/exocrine glands
• increased in doxycycline-treated mice

cellular
• increased in doxycycline-treated mice




Genotype
MGI:5755878
cn43
Allelic
Composition
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm18(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal crypt proliferation, differentiation and Paneth cell production




Genotype
MGI:5755879
cn44
Allelic
Composition
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm19(tetO-GFP,-cas9*)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• increased in doxycycline-treated mice
• doxycycline-treated mice exhibit dramatic hyper-proliferation and crypt expansion, blocked differentiation and ectopic Paneth cell production compared with control mice
• increased in doxycycline-treated mice

cellular
• increased in doxycycline-treated mice

endocrine/exocrine glands
• increased in doxycycline-treated mice




Genotype
MGI:5755882
cn45
Allelic
Composition
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• increased in doxycycline-treated mice
• doxycycline-treated mice exhibit dramatic hyper-proliferation and crypt expansion, blocked differentiation and ectopic Paneth cell production compared with control mice
• increased in doxycycline-treated mice

cellular
• increased in doxycycline-treated mice

endocrine/exocrine glands
• increased in doxycycline-treated mice




Genotype
MGI:4430578
cn46
Allelic
Composition
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Tg(Vil1-cre)997Gum/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm1(CAG-Sirt1)Dsin mutation (1 available); any Col1a1 mutation (166 available)
Tg(Vil1-cre)997Gum mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice do not develop tumors morbidities, including anemia and cachaxia, unlike Col1a1tm1(CAG-Sirt1)Dsin ApcMin heterozygotes
• mice develop fewer intestinal tumors than Col1a1tm1(CAG-Sirt1)Dsin ApcMin heterozygotes




Genotype
MGI:5306257
cn47
Allelic
Composition
Col1a1tm8(CAG-BDNF)Jae/Col1a1+
Mecp2tm1.1Jae/Y
Tg(Camk2a-cre)93Kln/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(CAG-BDNF)Jae mutation (0 available); any Col1a1 mutation (166 available)
Mecp2tm1.1Jae mutation (2 available); any Mecp2 mutation (43 available)
Tg(Camk2a-cre)93Kln mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• life span is significantly longer than in Mecp2 single hemizygous mice

behavior/neurological
N
• overexpression of BDNF improves locomotor function compared to Mecp2 single hemizygous mice at 6 weeks of age

nervous system
• decreased compared to wild-type littermates but modestly increased compared to Mecp2 single hemizygous mice
• firing rate is increased compared to Mecp2 single hemizygous mice




Genotype
MGI:5485200
cn48
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
H2az2Tg(Wnt1-cre)11Rth mutation (2 available); any H2az2 mutation (25 available)
Tg(CAG-cat,-lacZ)11Miya mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• in of all doxycycline-treated mice arising from neural crest-lineage cells




Genotype
MGI:5295750
cn49
Allelic
Composition
Col1a1tm1(CAG-Sirt2)Jmi/Col1a1+
Tg(Mpz-cre)26Mes/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(CAG-Sirt2)Jmi mutation (1 available); any Col1a1 mutation (166 available)
Tg(Mpz-cre)26Mes mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Delayed remyelination after nerve crush injury in Col1a1tm1(CAG-Sirt2)Jmi/Col1a1tm1(CAG-Sirt2)Jmi Tg(Mpz-cre)26Mes/0 mice

nervous system
• remyelination following nerve crush injury is delayed compared to in wild-type mice
• however, axon regeneration is normal
• remyelination following nerve crush injury is delayed compared to in wild-type mice

homeostasis/metabolism
• remyelination following nerve crush injury is delayed compared to in wild-type mice
• however, axon regeneration is normal




Genotype
MGI:6693445
cn50
Allelic
Composition
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Ssttm2.1(cre)Zjh/Sst+
Genetic
Background
involves: 129S4/SvJae * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg mutation (0 available); any Col1a1 mutation (166 available)
Ssttm2.1(cre)Zjh mutation (4 available); any Sst mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
N
• mice virally expressing a cre-dependent tet transactivator exhibit normal behavior in an open field and exploration of an elevated plus maze
• mice virally expressing a cre-dependent tet transactivator exhibit reduced long term memory in a cued threat-conditioning paradigm compared with wild-type
• however, supplementation with doxycycline rescues phenotype




Genotype
MGI:5582235
cn51
Allelic
Composition
Col1a1tm2(CAG-IDH2*R172K)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(CAG-IDH2*R172K)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mean survival after tamoxifen administration is 4 weeks

respiratory system
• mice show shortness of breath within 3-4 weeks of tamoxifen administration

behavior/neurological
• mice show signs of lethargy within 3-4 weeks of tamoxifen administration

cardiovascular system
• microscopic signs of circulatory congestion associated with cardiac failure are seen after tamoxifen administration
• cardiac muscle shows glycogen accumulation in tamoxifen treated mice
• myocyte dropout associated with myocyte hypertrophy and nuclear enlargement 4 weeks after tamoxifen administration
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administration, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• heart enlargement after tamoxifen administration
• seen after tamoxifen treatment
• 4 weeks after tamoxifen administration, mice exhibit end-stage cardiomyopathy characterized by severely decreased wall motion and increased dilatation without a change in heart rate
• 4 weeks after tamoxifen administration, mice show scarring of the hearts associated with accumulating collagen deposits
• fractional shortening is decreased in tamoxifen treated mice

cellular
• evidence of mitophagy is seen in tamoxifen treated mice, as indicated by the presence of double-membrane autophagosomes
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• disrupted cristae in cardiomyocytes of tamoxifen treated mice
• skeletal muscle shows abnormalities in mitochondria after tamoxifen administration
• in cardiomyocytes of tamoxifen treated mice
• cardiac defects in tamoxifen treated mice are associated with high levels of apoptosis in cardiomyocytes
• decrease in the steady-state mitochondrial TCA cycle intermediates in mice treated with tamoxifen

homeostasis/metabolism
• cardiac muscle shows glycogen accumulation in tamoxifen treated mice
• skeletal muscle shows glycogen accumulation in tamoxifen treated mice

muscle
• cardiac muscle shows glycogen accumulation in tamoxifen treated mice
• myocyte dropout associated with myocyte hypertrophy and nuclear enlargement 4 weeks after tamoxifen administration
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administration, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• 4 weeks after tamoxifen administration, mice exhibit end-stage cardiomyopathy characterized by severely decreased wall motion and increased dilatation without a change in heart rate
• 4 weeks after tamoxifen administration, mice show scarring of the hearts associated with accumulating collagen deposits
• fractional shortening is decreased in tamoxifen treated mice
• cardiac defects in tamoxifen treated mice are associated with high levels of apoptosis in cardiomyocytes
• cardiomyocytes show sarcomere degeneration and severe disorganization at 4 weeks after tamoxifen administration
• skeletal muscle shows abnormalities in sarcomere organization after tamoxifen administration
• cardiac Z disks are perturbed in mice treated with tamoxifen
• skeletal muscle shows abnormalities in sarcomere organization, mitochondria, and glycogen accumulation in tamoxifen treated mice
• skeletal muscle shows abnormalities in mitochondria after tamoxifen administration
• skeletal muscle shows glycogen accumulation in tamoxifen treated mice
• myofiber regeneration and degeneration are seen following tamoxifen administration
• seen following tamoxifen administration
• seen following tamoxifen administration

nervous system
• mice treated with tamoxifen exhibit vacuoles in multiple brain regions, including cortex, white matter, hippocampus, and brain stem
• vacuoles are filled with membranous debris at both myelinated axons and nonmyelinated naked axons but not in the neuron bodies
• diffuse vacuolar leukoencephalopathy in the white and gray matter throughout the CNS of tamoxifen treated mice
• vesicles are double-membraned, suggesting elevation in autophagy and mitochondrial abnormalities in axons of the brain
• however, no evidence of apoptosis or glycogen accumulation is seen in the brain

growth/size/body
• heart enlargement after tamoxifen administration




Genotype
MGI:5582193
cn52
Allelic
Composition
Col1a1tm3(CAG-IDH2*R140Q)Kkw/Col1a1+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(CAG-IDH2*R140Q)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mean survival after tamoxifen administration is 7 weeks

respiratory system
• mice show shortness of breath within 3-4 weeks of tamoxifen administration

behavior/neurological
• mice show signs of lethargy within 3-4 weeks of tamoxifen administration

cardiovascular system
• microscopic signs of circulatory congestion associated with cardiac failure are seen after tamoxifen administration
• myocyte dropout associated with myocyte hypertrophy and nuclear enlargement 4 weeks after tamoxifen administration
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administration, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• heart enlargement after tamoxifen administration
• seen after tamoxifen treatment
• 4 weeks after tamoxifen administration, mice exhibit end-stage cardiomyopathy characterized by severely decreased wall motion and increased dilatation without a change in heart rate
• 4 weeks after tamoxifen administration, mice show scarring of the hearts associated with accumulating collagen deposits
• fractional shortening is decreased in tamoxifen treated mice

cellular
• evidence of mitophagy is seen in tamoxifen treated mice, as indicated by the presence of double-membrane autophagosomes
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• disrupted cristae in cardiomyocytes of tamoxifen administration
• skeletal muscle shows abnormalities in mitochondria after tamoxifen administration
• in cardiomyocytes of tamoxifen treated mice
• cardiac defects following tamoxifen administration are associated with high levels of apoptosis in cardiomyocytes
• decrease in the steady-state mitochondrial tricarboxylic acid cycle intermediates in mice treated with tamoxifen

homeostasis/metabolism
• skeletal muscle shows glycogen accumulation in tamoxifen treated mice

nervous system
• mice treated with tamoxifen exhibit vacuoles in multiple brain regions, including cortex, white matter, hippocampus, and brain stem
• vacuoles are filled with membranous debris at both myelinated axons and nonmyelinated naked axons but not in the neuron bodies
• diffuse vacuolar leukoencephalopathy in the white and gray matter throughout the CNS of tamoxifen treated mice
• vesicles are double-membraned, suggesting elevation in autophagy and mitochondrial abnormalities in axons of the brain
• however, no evidence of apoptosis or glycogen accumulation is seen in the brain

muscle
• myocyte dropout associated with myocyte hypertrophy and nuclear enlargement 4 weeks after tamoxifen administration
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administration, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• mitochondrial abnormalities in cardiomyocytes after tamoxifen administraton, with disrupted cristae, smaller or swollen mitochondria, and decrease in the total mitochondrial counts and mitochondrial DNA content
• 4 weeks after tamoxifen administration, mice exhibit end-stage cardiomyopathy characterized by severely decreased wall motion and increased dilatation without a change in heart rate
• 4 weeks after tamoxifen administration, mice show scarring of the hearts associated with accumulating collagen deposits
• fractional shortening is decreased in tamoxifen treated mice
• cardiac defects following tamoxifen administration are associated with high levels of apoptosis in cardiomyocytes
• cardiomyocytes show sarcomere degeneration and severe disorganization at 4 weeks after tamoxifen administration
• skeletal muscle shows abnormalities in sarcomere organization after tamoxifen administration
• cardiac Z disks are perturbed in mice treated with tamoxifen
• skeletal muscle shows abnormalities in sarcomere organization, mitochondria, and glycogen accumulation in tamoxifen treated mice
• skeletal muscle shows abnormalities in mitochondria after tamoxifen administration
• skeletal muscle shows glycogen accumulation in tamoxifen treated mice

growth/size/body
• heart enlargement after tamoxifen administration




Genotype
MGI:6693444
cn53
Allelic
Composition
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg/Col1a1+
Tg(Prkcd-glc-1/CFP,-cre)EH124Gsat/0
Genetic
Background
involves: C57BL/6J * FVB/NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-GFP,-RNAi:Eef1a1)Mcg mutation (0 available); any Col1a1 mutation (166 available)
Tg(Prkcd-glc-1/CFP,-cre)EH124Gsat mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• mice virally expressing a cre-dependent tet transactivator exhibit impaired conditioned safety response to withdrawal of cued stimuli compared with wild-type mice
• however, acquisition of differential threat associative memory is normal
• increased exploration of an elevated plus maze in mice virally expressing a cre-dependent tet transactivator




Genotype
MGI:6378441
cx54
Allelic
Composition
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Genetic
Background
B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-URI1)Ndj mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)#Bjd mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die around 85 weeks of age, with a median survival of 76 weeks before complete liver failure

liver/biliary system
• 8 week old mice show anisokaryotic clusters resembling low-grade dysplastic nodules that develop into high-grade dysplastic nodules at 12 weeks of age that is similar to large liver dysplasia
• mice supplied with the nicotinamide riboside diet at 3 weeks of age do not show dysplastic lesions in the liver or DNA damage
• early hepatocellular carcinoma (HCC) emerges between 24-54 weeks of age, with mice showing low-grade and differentiated HCC at 54-65 weeks and 40% of mutants developing high-grade tumors occupying 20-60% of the liver between 65-75 weeks of age
• 25-50% of hepatocytes are Ki67+, suggesting aggressive tumors
• tumors are well/moderately differentiated, with 20% glandular/acinar and 80% trabecular
• however, no cholangiocarcinoma is seen
• mice treated with doxycycline to cease URI1 expression at 8 weeks of age for 24 weeks show abolished dysplastic foci and prevention of early tumors
• mice treated with doxycycline at 8 weeks until 60 weeks of age show prevention of tumor development
• when mice are treated with doxycycline at 24 weeks (when mice have high-grade dysplastic nodules/early HCC and adenomas) for 28 weeks, only residual anisokaryotic clusters are seen and no adenomas or HCCs are detected
• however, when treatment with doxycycline begins above 60 weeks of age, HCC does not regress
• prolonged nicotinamide riboside treatment prevents tumor development
• 8 week old mice exhibit liver fibrosis that increases over time until 24 weeks
• mice treated with doxycycline to cease URI1 expression at 8 weeks of age for 24 weeks show reduced liver fibrosis
• mice supplied with the nicotinamide riboside diet at 3 weeks of age have reduced liver fibrosis

neoplasm
• diethylnitrosamine (DEN)-treated mice develop HCC at 30 weeks of age
• early hepatocellular carcinoma (HCC) emerges between 24-54 weeks of age, with mice showing low-grade and differentiated HCC at 54-65 weeks and 40% of mutants developing high-grade tumors occupying 20-60% of the liver between 65-75 weeks of age
• 25-50% of hepatocytes are Ki67+, suggesting aggressive tumors
• tumors are well/moderately differentiated, with 20% glandular/acinar and 80% trabecular
• however, no cholangiocarcinoma is seen
• mice treated with doxycycline to cease URI1 expression at 8 weeks of age for 24 weeks show abolished dysplastic foci and prevention of early tumors
• mice treated with doxycycline at 8 weeks until 60 weeks of age show prevention of tumor development
• when mice are treated with doxycycline at 24 weeks (when mice have high-grade dysplastic nodules/early HCC and adenomas) for 28 weeks, only residual anisokaryotic clusters are seen and no adenomas or HCCs are detected
• however, when treatment with doxycycline begins above 60 weeks of age, HCC does not regress
• prolonged nicotinamide riboside treatment prevents tumor development
• metastases into lungs are seen

homeostasis/metabolism
• serum glucose levels are decreased in 65 week old mice
• serum albumin is increased in 65 week old mice
• NAD+ concentrations are reduced in 3- and 6-week old livers
• mice supplied with a nicotinamide riboside (NR) diet at 3 weeks of age show increased hepatic NAD+ concentrations
• alanine transaminase (ALT) levels are increased in 65 week old mice
• however, serum ALT levels are unchanged in 8 week old mice
• mice treated with doxycycline at 8 weeks until 60 weeks of age show normalization of ALT levels
• prolonged nicotinamide riboside treatment reduces ALT levels
• total bile acids are increased in 65 week old mice
• diethylnitrosamine (DEN)-treated mice develop HCC at 30 weeks of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
hepatocellular carcinoma DOID:684 OMIM:114550
J:217463




Genotype
MGI:6378452
cx55
Allelic
Composition
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
Genetic
Background
B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-URI1)Ndj mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)#Bjd mutation (0 available)
Trp53tm1Gev mutation (0 available); any Trp53 mutation (249 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice exhibit reduced survival compared to heterozygous Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd/0 mice

neoplasm
• mice exhibit accelerated liver tumorigenesis compared to single heterozygous Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd/0 mice, with 80% of mice showing aggressive hepatocellular carcinoma

liver/biliary system
• 8 week old mice show decreased cleaved caspase 3, Bax expression, collapsed fibers, Sirius Red staining and alanine transaminase levels, indicating suppressed hepatocyte apoptosis
• mice exhibit accelerated liver tumorigenesis compared to single heterozygous Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd/0 mice, with 80% of mice showing aggressive hepatocellular carcinoma

cellular
• 8 week old mice show decreased cleaved caspase 3, Bax expression, collapsed fibers, Sirius Red staining and alanine transaminase levels, indicating suppressed hepatocyte apoptosis




Genotype
MGI:5000008
cx56
Allelic
Composition
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
chimera involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• the founder mouse is sterile




Genotype
MGI:5527337
cx57
Allelic
Composition
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EML4/ALK)Kkw mutation (0 available); any Col1a1 mutation (166 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice exhibit a median survival of 7 to 8 weeks

neoplasm
• withdrawal of doxycycline leads to complete tumor regression
• ALK kinase inhibitor is a more effective therapy than chemotherapy in doxycycline-treated mice
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

growth/size/body
• in tumor-bearing, doxycycline-treated mice in the first 4 weeks

respiratory system
N
• untreated mice exhibit normal lung histology
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice




Genotype
MGI:5555860
cx58
Allelic
Composition
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Rag1tm1Mom/Rag1tm1Mom
Tg(KRT5-rtTA)T2D6Sgkd/0
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (166 available)
Rag1tm1Mom mutation (56 available); any Rag1 mutation (132 available)
Tg(KRT5-rtTA)T2D6Sgkd mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
N
• doxycycline-treated mice exhibit normal keratinocyte proliferation and activation
• in doxycycline-treated mice but smaller than in mice with wild-type Rag1
• in doxycycline-treated mice but less so than in mice with wild-type Rag1




Genotype
MGI:5316652
cx59
Allelic
Composition
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-YAP1*)Fcam mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)#Bjd mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• resistance to Fas-mediated apoptosis after doxycycline withdrawal
• after doxycycline withdrawal
• 4-fold after doxycycline withdrawal for 35 days
• however, increased liver size is reversible by treatment with doxycycline
• after doxycycline withdrawal
• however, increased liver weight is reversible by treatment with doxycycline
• after doxycycline withdrawal
• dysplastic hepatocytes with irregular, enlarged nuclei and a high to nuclear to cytoplasmic ratio after doxycycline withdrawal

cellular
• resistance to Fas-mediated apoptosis after doxycycline withdrawal
• after doxycycline withdrawal

growth/size/body
• 4-fold after doxycycline withdrawal for 35 days
• however, increased liver size is reversible by treatment with doxycycline
• after doxycycline withdrawal
• however, increased liver weight is reversible by treatment with doxycycline
• after doxycycline withdrawal




Genotype
MGI:3703249
cx60
Allelic
Composition
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Pou5f1)Jae mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice with doxycycline-induced ectopic Oct4 expression become morbid after 3-5 days of treatment and usually die after 5-10 days of treatment
• however, if doxycycline treatment is stopped after 5 days mice completely recover

digestive/alimentary system
• after doxycline treatment, dysplastic cells are found in the entire epithelium; cells have structural and cytological dysplasia which mimics adenocarcinoma
• the proximal part of the small intestine is most severely affected by doxycycline treatment with abnormal cells often almost obstructing the lumen
• after 5 days of doxycycline treatment, proliferative zone expands; postmitotic, differentiated cells lining the villus are replaced
• upon cessation of treatment, cells migrate to final destinations and differentiate resulting in restoration of normal morphology
• in doxycycline treated mice, cells in the forestomach show a marked atypia and increased mitotic activity
• pyloric mucosa contains lesions resembling high grade-dysplasia in doxycycline treated mice
• hyperplastic fundic glands are seen in doxycycline treated mice
• in doxycycline treated mice, forestomach epithelium is thickened and stomach shows lack of differentiation into granular and cornified cell layers compared to control mice
• the thickened epithelium consists of atypical cells with enlarged nuclei and prominent nucleoli
• after doxycycline treatment, mice display severe dysplasia and increased proliferation
• cells show atypia and increased mitotic activity throughout the squamous epithelial layer in doxycycline treated mice

homeostasis/metabolism
• after 3-5 days of doxycycline treatment, animals display severe dehydration

cellular
• abnormal cell proliferation is observed in several organs after 2 days of Oct4-induction
• however, complete reversion is seen with withdrawal of doxycycline treatment

behavior/neurological
• animals become lethargic with doxycycline treatment within 3-5 days

hematopoietic system
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice
• in doxycycline treated mice

immune system
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice
• in doxycycline treated mice

neoplasm
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen

integument
• increased numbers of immature cells in the hair follicles of the skin are seen after 5-10 days of doxycycline
• after 5-10 days of doxycycline treatment, mice show mild to moderate epidermal dysplasia with a decrease in differentiation in dysplastic cells
• in doxycycline treated mice, tumors originating from the outer-root-sheath progenitors and invading the subcutaneous layer are seen

endocrine/exocrine glands
• hyperplastic fundic glands are seen in doxycycline treated mice
• atrophy and absence of CD4, CD8 double positive cells in doxycycline treated mice




Genotype
MGI:4822382
cx61
Allelic
Composition
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm6(tetO-MSI2)Jae mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease

hematopoietic system
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit a decrease in myeloid progenitor and myeloid erythrocroid progenitor cells compared with mice reconstituted with wild-type bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• at 6 weeks, but not 16 weeks, in wild-type mice reconstituted with bone marrow and treated with doxycyline
• doxycycline-treated mice exhibit an expansion of hematopoietic stem cells (HSCs) due to preferential expansion of short term HSC compared with wild-type mice
• wild-type mice reconstituted with bone marrow and treated with doxycycline exhibit an increase in HSCs, hematopoietic progenitor cells, and long term HSCs compared with mice reconstituted with wild-type bone marrow
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1

liver/biliary system
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1

neoplasm
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit an increase in the number of leukemic blasts and infiltration with immature myeloid cells compared with similarly treated wild-type mice reconstituted with wild-type bone marrow

immune system
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 die within 14 days due to rapid and lethal myeloproliferative disease
• at 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• at 6 and 16 weeks in wild-type mice reconstituted with bone marrow and treated with doxycyline
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1

growth/size/body
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1 exhibit increased liver size compared with similarly treated mice reconstituted with wild-type bone marrow
• modestly in doxycycline-treated wild-type mice reconstituted with bone marrow
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1
• in wild-type mice reconstituted with bone marrow, treated with doxycyline, and transduced with BCR-ABL1




Genotype
MGI:4999980
cx62
Allelic
Composition
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• doxycycline-treated mice are normal




Genotype
MGI:4999985
cx63
Allelic
Composition
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice with lymphoma exhibit median survival of 7.4 months

skeleton
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice
• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice

integument
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice
• in mice treated with doxycycline beyond 20 weeks
• however, reactivation after 4 weeks by doxycycline withdrawal prevents hair loss
• in mice treated with doxycycline beyond 20 weeks

homeostasis/metabolism
• in mice treated with doxycycline at E8.5
• however, mice transiently treated with doxycycline between E8.5 and E12.5 do not exhibit edema

limbs/digits/tail
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit extra digits (total 5 to 9) that are largely unsegmented and duplicated along their length compared with wild-type mice
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice
• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice

growth/size/body
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout
• runting in mice treated with doxycycline 1 to 2 days prior to birth
• in mice treated with doxycycline 1 to 2 days prior to birth
• at E14.5 and E18.5 in mice treated with doxycycline at E8.5

neoplasm
• in mice treated with doxycycline from 4 to 6 weeks of age
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age
• in mice treated with doxycycline from 4 to 6 weeks of age

craniofacial
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout

endocrine/exocrine glands
• in mice treated with doxycycline from 4 to 6 weeks of age

immune system
• in mice treated with doxycycline from 4 to 6 weeks of age

hematopoietic system
• in mice treated with doxycycline from 4 to 6 weeks of age




Genotype
MGI:4999987
cx64
Allelic
Composition
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice with lymphoma exhibit median survival or 5.3 months

neoplasm
• in mice treated with doxycycline from 4 to 6 weeks of age
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age
• in mice treated with doxycycline from 4 to 6 weeks of age

integument
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice
• in mice treated with doxycycline beyond 20 weeks
• however, reactivation after 4 weeks of doxycycline prevents hair loss
• in mice treated with doxycycline beyond 20 weeks

craniofacial
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout

growth/size/body
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout
• runting in mice treated with doxycycline 1 to 2 days prior to birth
• in mice treated with doxycycline 1 to 2 days prior to birth

endocrine/exocrine glands
• in mice treated with doxycycline from 4 to 6 weeks of age

immune system
• in mice treated with doxycycline from 4 to 6 weeks of age

hematopoietic system
• in mice treated with doxycycline from 4 to 6 weeks of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
lymphoid leukemia DOID:1037 J:171191




Genotype
MGI:5000007
cx65
Allelic
Composition
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely

growth/size/body
• in doxycycline-treated mice

cellular
• doxycycline-treated mice exhibit cell cycle arrest unlike control mice




Genotype
MGI:5000010
cx66
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• when treated in utero with doxycycline, mice die shortly after birth

cellular
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells
• however, withdrawal of doxcycline restores proliferation

normal phenotype
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype




Genotype
MGI:5000011
cx67
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely

digestive/alimentary system
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice
• however, withdrawal of doxycycline reverses villus atrophy
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice

hematopoietic system
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice

growth/size/body
• in doxycycline-treated adult mice
• however, mice regain weight after withdrawal of doxycycline

cellular
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice




Genotype
MGI:5000012
cx68
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• when treated in utero with doxycycline, mice die shortly after birth

cellular
• doxycycline-treated mouse embryonic fibroblasts arrest in S phase with increased DNA content compared with untreated cells
• doxycycline-treated mouse embryonic fibroblasts exhibit early cellular replicative senescence compared with untreated cells
• however, withdrawal of doxcycline restores proliferation

normal phenotype
• mice treated with doxycycline during adulthood exhibit no abnormal phenotype




Genotype
MGI:5000013
cx69
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice treated with doxycycline between 5 and 10 weeks of age die prematurely

digestive/alimentary system
• doxycycline-treated adult mice exhibit atrophy of intestinal epithelium unlike control mice
• however, withdrawal of doxycycline reverses villus atrophy
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice

hematopoietic system
• doxycycline-treated adult mice exhibit decreased erythroid precursors in the bone marrow unlike in control mice

growth/size/body
• in doxycycline-treated adult mice
• however, mice regain weight after withdrawal of doxycycline

cellular
• doxycycline-treated adult mice exhibit decreased proliferation and cell cycle arrest in the intestinal epithelium unlike control mice




Genotype
MGI:5051636
cx70
Allelic
Composition
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Tcfap2c)Hsc mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+ mice show increased proliferation and induced hepatic steatosis

mortality/aging
• within 6 to 7 days of doxycycline treatment

homeostasis/metabolism
• after doxycycline treatment, mice exhibit increased serum levels of aspartate transaminase, alanine transaminase, alkaline phosphatase, lipase, amylase, lactate dehydrogenase levels compared with control mice
• after doxycycline treatment
• after doxycycline treatment
• after doxycycline treatment
• after doxycycline treatment
• after doxycycline treatment

liver/biliary system
• after doxycycline treatment
• after doxycycline treatment
• after doxycycline treatment
• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria and increased mitophagy compared to in cells from control mice
• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria
• after doxycycline treatment, mice exhibit microvesicular steatosis unlike control mice
• after doxycycline treatment

digestive/alimentary system
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice
• after doxycycline treatment, the number of terminally differentiated intestinal cells (absorptive enterocytes, goblet cells, Paneth, cells and enteroendocrine cells) is reduced compared to in control mice
• after doxycycline treatment
• after doxycycline treatment, the ratio of crypt length to villus length in the duodenum, jejunum, and ileum is increased compared to in control mice

endocrine/exocrine glands
• after doxycycline treatment, mice exhibit pancreatic injury unlike control mice

behavior/neurological
• after doxycycline treatment

growth/size/body
• after doxycycline treatment

immune system
N
• doxycycline-treated mice do not exhibit induction of inflammatory processes

cellular
• after doxycycline treatment, hepatocytes exhibit abnormally bright mitochondria
• after doxycycline treatment
• after doxycycline treatment, the proliferative zone is expanded to cover crypt and villus compared to in control mice
• after doxycycline treatment




Genotype
MGI:5304757
cx71
Allelic
Composition
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-RNAi:Rps19)Karl mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment

hematopoietic system
• decrease in the frequency of bipotential megakaryocytic-erythroid cells and preGM/GMP progenitor cells at 7 weeks after doxycycline treatment
• by 10 days after doxycycline treatment
• absolute numbers of all hematopoietic stem and progenitor cells are reduced at 7 weeks after doxycycline treatment
• seven weeks after doxycycline treatment
• decrease in the frequency or proerythroblasts in the bone marrow by 10 days after doxycycline treatment
• seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• preMegE and preCFU-E/CFU-E progenitors show impaired proliferation and increased apoptosis following doxycycline treatment

immune system
• two and seven weeks after doxycycline treatment

growth/size/body
• following doxycycline treatment
• less pronounced than in homozygous mice

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Diamond-Blackfan anemia DOID:1339 OMIM:PS105650
J:179085




Genotype
MGI:5304759
cx72
Allelic
Composition
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-RNAi:Rps19)Karl mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike homozygous mice, heterozygotes survive at least 3 months following doxycycline treatment

hematopoietic system
• seven weeks after doxycycline treatment
• two weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• seven weeks after doxycycline treatment
• two and seven weeks after doxycycline treatment
• two weeks after doxycycline treatment

growth/size/body
• following doxycycline treatment
• less pronounced than in homozygous mice

immune system
• two and seven weeks after doxycycline treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Diamond-Blackfan anemia DOID:1339 OMIM:PS105650
J:179085




Genotype
MGI:5316663
cx73
Allelic
Composition
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-YAP1*)Fcam mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice become ill and must be euthanized 4-6 days after doxycycline treatment

digestive/alimentary system
• mature goblet cells are absent 5 days after doxycycline treatment
• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal
• in doxycycline-treated mice
• severe dysplasia in doxycycline-treated mice
• Paneth cells are absent 5 days after doxycycline treatment
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal

endocrine/exocrine glands
• in doxycycline-treated mice
• Paneth cells are absent 5 days after doxycycline treatment
• however, the absence of Paneth cells is reversed by doxycycline-withdrawal
• in doxycycline-treated mice
• ductal metaplasia of pancreatic acinar cells in doxycycline-treated mice

cellular
• mature goblet cells are absent 5 days after doxycycline treatment
• however, the absence of mature goblet cells is reversed by doxycycline-withdrawal and administration of dipenzazepine increased goblet cell numbers
• increased proliferation of epithelium cells in the crypt regions, villus regions and at the tip of the villi of undifferentiated progenitor cells in doxycycline-treated mice
• dipenzazepine administration decreases cell proliferation in the intestine of mice treated with doxycycline
• however, proliferation of undifferentiated cells is reversed by doxycycline-withdrawal
• in the epidermis of doxycycline-treated mice

homeostasis/metabolism
• absent in the small intestine 5 days after doxycycline treatment

integument
• in doxycycline-treated mice

growth/size/body
• in doxycycline-treated mice




Genotype
MGI:5430595
cx74
Allelic
Composition
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Yap1*)Lrsn mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die 10 days after treatment with doxycycline




Genotype
MGI:5485198
cx75
Allelic
Composition
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EWSR1/ATF1)Yasu mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• after 3 to 10 months of doxycycline-treated mice with median survival of 20 weeks

neoplasm
• in doxycycline-treated mice following withdrawal of doxycycline
• in the trunks, heads, limbs, and whisker pads of all doxycycline-treated mice after 3 months arising from neural crest-lineage cells

cellular
• in doxycycline-treated mouse embryonic fibroblasts

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
clear cell sarcoma DOID:4233 J:194505




Genotype
MGI:5585616
cx76
Allelic
Composition
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Cyp26b1)Mfra mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• mice treated with doxycycline at E8.5 exhibit smaller jugular lymph sac at E 14.5 compared with control mice




Genotype
MGI:5586502
cx77
Allelic
Composition
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Fosl1,-DsRed)Wag mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• periportal with immune infiltrate in doxycycline-treated mice

skeleton
• in doxycycline-treated mice at necropsy

growth/size/body
• in doxycycline-treated mice
• in doxycycline-treated mice at necropsy

behavior/neurological
• in doxycycline-treated mice

homeostasis/metabolism
• sometimes in doxycycline-treated mice at necropsy

hematopoietic system
• in doxycycline-treated mice at necropsy

immune system
• in doxycycline-treated mice at necropsy




Genotype
MGI:5754807
cx78
Allelic
Composition
Col1a1tm1(tetO-U2AF1*S34F)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-U2AF1*S34F)Mjwa mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• lethally-irradiated mice transplanted with mutant bone marrow and treated with doxycycline exhibit altered hematopoiesis, showing peripheral blood leukopenia, and changes in the distribution of mature hematopoietic lineages in the peripheral blood and spleen (reduction in B cells and monocytes, increase in neutrophils) and an increase in the frequency of progenitor cells in the bone marrow and spleen as well as the frequency of progenitor cells that are cycling in the bone marrow
• however, lethally-irradiated mice transplanted with mutant bone marrow and treated with doxycycline do not develop myelodysplastic syndrome or acute myeloid leukemia after at least 1 year of continuous doxycycline




Genotype
MGI:5754809
cx79
Allelic
Composition
Col1a1tm2(tetO-U2AF1)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-U2AF1)Mjwa mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• transplantation of bone marrow from mutants into lethally-irradiated recipient mice treated with doxycycline does not result in altered hematopoiesis




Genotype
MGI:5911575
cx80
Allelic
Composition
Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• lineage skewing is seen following prolonged doxycycline exposure (30 days)
• in the splenic parenchyma
• decrease in the Ter119+ cell population
• decrease in the proportion of B cell population (B220+)
• increase in the proportion of myelomonocytic (Cd11b+/Gr1+) and erythroid (CD71+/Ter119+) cells
• increased amount of early erythroid (CD71+/Ter119+) cells in the spleen
• increase in nuclear size in sorted Lineage-/c-Kit+ progenitor cells not associated with an increase of genomic material or instability

immune system
• decrease in the proportion of B cell population (B220+)




Genotype
MGI:5911576
cx81
Allelic
Composition
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• lineage skewing is seen following prolonged doxycycline exposure (30 days)
• in the splenic parenchyma
• decrease in the Ter119+ cell population
• hypercellular bone marrow with erythroid and megakaryocytic hypoplasia and marked myeloid hyperplasia
• in the GFP+ cells in the bone marrow
• in peripheral blood of aged mice
• decrease in the proportion of B cell population (B220+)
• increase in the proportion of myelomonocytic (Cd11b+/Gr1+) and erythroid (CD71+/Ter119+) cells
• increased amount of early erythroid (CD71+/Ter119+) cells in the spleen
• aged mice show marked expansion of myeloid elements (granulocytic > monocytic) in the peripheral blood
• increase in nuclear size in sorted Lineage-/c-Kit+ progenitor cells not associated with an increase of genomic material or instability
• decrease in the number of GFP+ cells in the long-term (CD150+) and short-term (CD150-/CD48-) subsets
• compensated for with an increase in the CD150+/CD48+ multipotent progenitor subset

immune system
• aged mice show marked expansion of myeloid elements (granulocytic > monocytic) in the peripheral blood
• in peripheral blood of aged mice
• decrease in the proportion of B cell population (B220+)

growth/size/body

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myeloproliferative neoplasm DOID:2226 J:229031




Genotype
MGI:5911578
cx82
Allelic
Composition
Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• lineage skewing is seen following prolonged doxycycline exposure (30 days)
• decrease in the proportion of B cell population (B220+)
• increase in the proportion of myelomonocytic (Cd11b+/Gr1+) and erythroid (CD71+/Ter119+) cells
• increase in nuclear size in sorted Lineage-/c-Kit+ progenitor cells not associated with an increase of genomic material or instability
• decrease in the number of GFP+ cells in the long-term (CD150+) and short-term (CD150-/CD48-) subsets

immune system
• decrease in the proportion of B cell population (B220+)




Genotype
MGI:5313420
cx83
Allelic
Composition
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm10(tetO-Dnmt3b_i3)Jae mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes




Genotype
MGI:5469373
cx84
Allelic
Composition
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-CTNNB1)Tcd mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• doxycycline-treated mice exhibit normal villus compartment
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice
• upon withdrawal of doxycycline
• increased in the crypt compartment of doxycycline-treated mice
• doxycycline-treated mice exhibit partially altered intestinal differentiation compared with control mice
• enlarged crypts in doxycycline-treated mice
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment

growth/size/body
• in docycycline-treated mice

endocrine/exocrine glands
• enlarged crypts in doxycycline-treated mice
• however, withdrawal of doxycycline leads to a rapid regression of the crypt compartment

cellular
• docycycline-treated mice exhibit apoptosis all along the enlarged crypt axis instead of being restricted to the bottom of the crypt as in control mice
• upon withdrawal of doxycycline
• increased in the crypt compartment of doxycycline-treated mice




Genotype
MGI:5437856
cx85
Allelic
Composition
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Deptor)Dmsa mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion
• in doxycycline treated mice on a high fat diet
• MEFs treated with doxycycline and differentiated in adipocytes show increased triglyceride accumulation

adipose tissue
• in doxycycline treated mice on a high fat diet

liver/biliary system
• in doxycycline treated mice on a high fat diet
• in doxycycline treated mice on a high fat diet

growth/size/body
• doxycycline treated mice gain more weight on a high fat diet; not caused by a difference in food intake or locomotion
• in doxycycline treated mice on a high fat diet




Genotype
MGI:5313423
cx86
Allelic
Composition
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm12(tetO-Dnmt3a_i1)Jae mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes




Genotype
MGI:4430577
cx87
Allelic
Composition
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm1(CAG-Sirt1)Dsin mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop intestinal tumors in the duodenum and ileum

growth/size/body
• at 16 weeks

hematopoietic system
• at 16 weeks

digestive/alimentary system
• mice develop intestinal tumors in the duodenum and ileum




Genotype
MGI:6377634
cx88
Allelic
Composition
ApcMin/Apc+
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm11(tetO-Nup88)Jvd mutation (0 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• doxycycline (dox)-treated mice show increased incidence of colon tumors compared to single ApcMin heterozygotes, but tumor multiplicity or size is unaffected and there is no difference in the multiplicity of small intestinal polyps
• mice in which dox is discontinued 30 days before analysis, show the same incidence of colon tumors as in mice with continuous administration of dox

neoplasm
• doxycycline (dox)-treated mice show increased incidence of colon tumors compared to single ApcMin heterozygotes, but tumor multiplicity or size is unaffected and there is no difference in the multiplicity of small intestinal polyps
• mice in which dox is discontinued 30 days before analysis, show the same incidence of colon tumors as in mice with continuous administration of dox




Genotype
MGI:5313421
cx89
Allelic
Composition
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm11(tetO-Dnmt3b_i6)Jae mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• doxycycline-treated mice develop intestinal adenomas at the same rate as in Apcmin heterozygotes




Genotype
MGI:5313419
cx90
Allelic
Composition
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (156 available)
Col1a1tm9(tetO-Dnmt3b_i1)Jae mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes
• doxycycline-treated mice exhibit increased size of microadenomas compared with Apcmin heterozygotes

cellular
• doxycycline-treated mice exhibit loss of imprinting and increased expression of Igf2 compared with control mice
• doxycycline-treated mice exhibit biallelic methylation of H19 differentially methylated region in tumors and normal colon epithelial cells compared with control mice
• doxycycline-treated mice exhibit hypermethylation of Sfrp2, Sfrp4 and Sfrp5 in tumors and normal colon epithelial cells unlike control mice
• however, mice exhibit normal methylation of of Snrpn differentially methylated region in tumors and normal colon epithelial cells, and global DNA methylation

digestive/alimentary system
• doxycycline-treated mice develop more macro- and microadenomas in the small intestinal and, to a lesser extent colon, compared with Apcmin heterozygotes




Genotype
MGI:5294614
cx91
Allelic
Composition
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-LIN28B)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice

homeostasis/metabolism
• following doxycycline treatment mice gain less weight when fed a high fat diet compared to wild-type mice
• following doxycycline treatment average fasting glucose is less than 50 mg/dL
• following doxycycline treatment on a normal or high fat diet
• following doxycycline treatment




Genotype
MGI:5294615
cx92
Allelic
Composition
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda mutation (1 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• following doxycycline treatment
• following doxycycline treatment

homeostasis/metabolism
• in the fed state following doxycycline treatment
• during a glucose tolerance test in doxycycline treated mice
• however, no difference in insulin sensitivity is detected following doxycycline treatment
• following doxycycline treatment on a normal or high fat diet




Genotype
MGI:5586499
cx93
Allelic
Composition
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Fosl2,-DsRed)Wag mutation (0 available); any Col1a1 mutation (166 available)
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular

skeleton
• decreased osteoclast surface
• increased osteoblast surface
• increased bone formation

homeostasis/metabolism
• in response to glucose stimulation
• in the pancreas
• in mice fed a normal diet or a high fat diet
• however, infection with Adipoq-expressing adenovirus rescues serum glucose levels in mice fed a normal or high fat diet
• in fasted mice fed a normal diet
• in mice fed a normal diet or a high fat diet
• however, bone insulin levels are normal and infection with Adipoq-expressing adenovirus rescues levels in mice fed a normal, but not high fat, diet
• in mice fed a normal diet or high fat diet
• however, infection with Adipoq-expressing adenovirus restores glucose tolerance in mice fed a normal diet
• in mice fed a normal diet or high fat diet
• however, infection with Adipoq-expressing adenovirus restores insulin sensitivity in mice fed a normal diet

growth/size/body
• under normal diet and high fat diet conditions
• however, infection with Adipoq-expressing adenovirus rescues body weight in mice fed a normal, but not high fat, diet

endocrine/exocrine glands
• in response to glucose stimulation
• in the pancreas

adipose tissue
N
• mice exhibit normal adipocyte number and size
• under normal diet and high fat diet conditions
• however, infection with Adipoq-expressing adenovirus rescues fat pad weight in mice fed a normal or high fat diet

hematopoietic system
• decreased osteoclast surface

immune system
• decreased osteoclast surface




Genotype
MGI:5502570
cx94
Allelic
Composition
Col1a1tm1(tetO-CDKN2A)Ibp/Col1a1+
Tg(KRT5-rtTA)#Glk/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-CDKN2A)Ibp mutation (0 available); any Col1a1 mutation (166 available)
Tg(KRT5-rtTA)#Glk mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• dysfunctional hair follicle stem cells in doxycycline-treated mice due to blockage of proliferation
• noticeable after 10 days and pronounced by 6 weeks in doxycycline-treated mice
• bulge stem cells in doxycycline-treated mice fail to enter into the cell cycle and initiate anagen with follicles remaining in a telogen-like state unlike in control mice
• resilencing in doxycycline re-treated mice prevents hair follicle growth unlike in control mice
• however, withdrawal of doxycycline restores entry into anagen
• in some doxycycline-treated mice
• after 2 days, doxycycline-treated mice exhibit decreased proliferation and increased apoptosis of basal epidermal cells compared with control mice
• after 1 week, mice exhibit hyperproliferation of basal cells that decreases after longer induction times and increased cellular replicative senescence compared with control mice
• however, apoptosis rates are normal after 1 week of induction and removal of doxycycline prevents further increases in senescence

cellular
• after 1 week, doxycycline-treated mice exhibit increased cellular senescence in the epidermis compared with control mice
• however, removal of doxycycline prevents further increases in senescence and treatment with TPA does not increase senescence




Genotype
MGI:5555858
cx95
Allelic
Composition
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (166 available)
Tg(KRT5-rtTA)T2D6Sgkd mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• after doxycycline treatment

integument
• with increased survival in doxycycline-treated mice
• in doxycycline-treated mice
• after doxycycline treatment
• in doxycycline-treated mice
• cornified epidermis in affected skin of doxycycline-treated mice
• in doxycycline-treated mice
• in doxycycline-treated mice
• however, MMP inhibitor impairs hyperplasia
• dry and scaly lesions on the affected skin of doxycycline-treated mice
• in doxycycline-treated mice
• affected skin of doxycycline-treated mice

immune system
N
• doxycycline-treated mice exhibit normal spleen weight
• in the skin of doxycycline-treated mice
• in the skin of doxycycline-treated mice
• however, doxycycline withdrawal restores CD4+ T cell numbers
• in doxycycline-treated mice

neoplasm
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks
• however, sulindac treatment reduces the number and size of tumors
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks

growth/size/body
• after doxycycline treatment

digestive/alimentary system
• mild phenotype in doxycycline-treated mice

homeostasis/metabolism
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks
• however, sulindac treatment reduces the number and size of tumors

cellular
• with increased survival in doxycycline-treated mice

hematopoietic system
• in the skin of doxycycline-treated mice
• in the skin of doxycycline-treated mice
• however, doxycycline withdrawal restores CD4+ T cell numbers




Genotype
MGI:5586552
cx96
Allelic
Composition
Col1a1tm4(tetO-Jun/Fosl2)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm4(tetO-Jun/Fosl2)Wag mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)5Bjd mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• compared with control mice when fed a high fat diet
• mice fed a high fat diet do not develop steatohepatitis unlike control mice

homeostasis/metabolism
• compared with control mice when fed a high fat diet




Genotype
MGI:5586504
cx97
Allelic
Composition
Col1a1tm2(tetO-Fosl2,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm2(tetO-Fosl2,-DsRed)Wag mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)5Bjd mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• compared with control mice when fed a high fat diet
• mice fed a high fat diet do not develop steatohepatitis unlike control mice

homeostasis/metabolism
N
• mice subjected to acetaminophen-induced hepatotoxicity exhibit a normal response
• compared with control mice when fed a high fat diet




Genotype
MGI:5586503
cx98
Allelic
Composition
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Tg(Cebpb-tTA)5Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm3(tetO-Fosl1,-DsRed)Wag mutation (0 available); any Col1a1 mutation (166 available)
Tg(Cebpb-tTA)5Bjd mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• in mice exposed to DCC

mortality/aging
N
• mice are viable

homeostasis/metabolism
• in mice exposed to DCC
• mild in mice fed a high fat diet
• mild in mice fed a high fat diet
• compared with control mice when fed a high fat diet (J:210545)
• reversion of high fat diet-induced elevations in alanine transaminase level following withdrawal of doxycycline (J:210545)
• in mice exposed to DCC (J:213764)
• slightly worse than in control mice fed a high fat diet
• slightly worse than in control mice when fed a high fat diet
• relative to body weight in mice exposed to DCC compared with control mice
• compared with control mice when fed a high fat diet
• reversion of high fat diet-induced steatosis following withdrawal of doxycycline
• however, adenorival Pparg restores diet-induced steatosis
• mice exposed to DCC exhibit reduced liver damage (increased relative liver weight and reduced ALT levels) compared with control mice
• mice subjected to acetaminophen-induced hepatotoxicity exhibit reduced liver damage compared with control mice

liver/biliary system
N
• mice exhibit no signs of liver fibrosis and serum parameters
• reduced compared with control mice fed a high fat diet
• less pale livers with a reduction in lipid droplets than in control mice when a high fat diet
• in mice exposed to DCC
• compared with control mice when fed a high fat diet
• reversion of high fat diet-induced steatosis following withdrawal of doxycycline
• however, adenorival Pparg restores diet-induced steatosis
• compared with control mice when fed a high fat diet
• in mice fed a high fat diet following withdrawal of doxycycline
• reduction in lipid droplets compared with control mice when fed a high fat diet
• reversion of high fat diet-induced steatosis following doxycycline treatment
• however, adenorival Pparg restores diet-induced steatosis

immune system
• reduced compared with control mice fed a high fat diet




Genotype
MGI:5000006
cx99
Allelic
Composition
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• half of mice treated with doxycycline between 5 and 10 weeks of age die prematurely

growth/size/body
• in doxycycline-treated mice

cellular
• doxycycline-treated mice exhibit cell cycle arrest in the liver, spleen, and intestine unlike control mice




Genotype
MGI:5000009
cx100
Allelic
Composition
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely

growth/size/body
• in doxycycline-treated mice




Genotype
MGI:5000005
cx101
Allelic
Composition
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely

growth/size/body
• in doxycycline-treated mice

cellular
• doxycycline-treated mice exhibit cell cycle arrest in the liver, spleen, and intestine unlike control mice




Genotype
MGI:5000014
cx102
Allelic
Composition
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * NMRI
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe mutation (0 available); any Col1a1 mutation (166 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (31 available); any Gt(ROSA)26Sor mutation (1098 available)
Tg(CMV-rtTA)4Bjd mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice treated with doxycycline between 5 and 10 weeks of age die prematurely

growth/size/body
• in doxycycline-treated mice




Genotype
MGI:5572909
cx103
Allelic
Composition
Atg5tm1.1Myok/Atg5tm1.1Myok
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1+
Genetic
Background
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Atg5tm1.1Myok mutation (0 available); any Atg5 mutation (29 available)
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae mutation (1 available); any Col1a1 mutation (166 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• mouse embryonic fibroblasts cultured in embryonic stem cell media fail to form induced pluripotent stem cells unlike wild-type cells





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/25/2025
MGI 6.24
The Jackson Laboratory